Sign In
Buy ORINF
Orion New B Shs Earnings Calls
| Release date | Feb 12, 2026 |
| EPS estimate | $2.32 |
| EPS actual | $2.17 |
| EPS Surprise | -6.47% |
| Revenue estimate | 420M |
| Revenue actual | 816.637M |
| Revenue Surprise | 94.44% |
| Release date | Oct 28, 2025 |
| EPS estimate | $0.81 |
| EPS actual | $0.80 |
| EPS Surprise | -0.497% |
| Revenue estimate | 706.55M |
| Revenue actual | 496.014M |
| Revenue Surprise | -29.80% |
| Release date | Jul 18, 2025 |
| EPS estimate | $0.610 |
| EPS actual | $0.695 |
| EPS Surprise | 13.93% |
| Revenue estimate | 430.158M |
| Revenue actual | 490.404M |
| Revenue Surprise | 14.01% |
| Release date | Apr 23, 2025 |
| EPS estimate | $0.425 |
| EPS actual | $0.478 |
| EPS Surprise | 12.39% |
| Revenue estimate | 372.441M |
| Revenue actual | 388.73M |
| Revenue Surprise | 4.37% |
Last 4 Quarters for Orion New B Shs
Below you can see how ORINF performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Apr 23, 2025 |
| Price on release | $48.65 |
| EPS estimate | $0.425 |
| EPS actual | $0.478 |
| EPS surprise | 12.39% |
| Date | Price |
|---|---|
| Apr 17, 2025 | $48.65 |
| Apr 18, 2025 | $48.65 |
| Apr 21, 2025 | $48.65 |
| Apr 22, 2025 | $48.65 |
| Apr 23, 2025 | $48.65 |
| Apr 24, 2025 | $48.65 |
| Apr 25, 2025 | $48.65 |
| Apr 28, 2025 | $48.65 |
| Apr 29, 2025 | $48.65 |
| 4 days before | 0% |
| 4 days after | 0% |
| On release day | 0% |
| Change in period | 0% |
| Release date | Jul 18, 2025 |
| Price on release | $43.02 |
| EPS estimate | $0.610 |
| EPS actual | $0.695 |
| EPS surprise | 13.93% |
| Date | Price |
|---|---|
| Jul 14, 2025 | $48.65 |
| Jul 15, 2025 | $48.65 |
| Jul 16, 2025 | $48.65 |
| Jul 17, 2025 | $48.65 |
| Jul 18, 2025 | $43.02 |
| Jul 21, 2025 | $48.65 |
| Jul 22, 2025 | $48.65 |
| Jul 23, 2025 | $48.65 |
| Jul 24, 2025 | $48.65 |
| 4 days before | -11.57% |
| 4 days after | 13.09% |
| On release day | 13.09% |
| Change in period | 0% |
| Release date | Oct 28, 2025 |
| Price on release | $81.30 |
| EPS estimate | $0.81 |
| EPS actual | $0.80 |
| EPS surprise | -0.497% |
| Date | Price |
|---|---|
| Oct 22, 2025 | $81.30 |
| Oct 23, 2025 | $81.30 |
| Oct 24, 2025 | $81.30 |
| Oct 27, 2025 | $81.30 |
| Oct 28, 2025 | $81.30 |
| Oct 29, 2025 | $81.30 |
| Oct 30, 2025 | $81.30 |
| Oct 31, 2025 | $81.30 |
| Nov 03, 2025 | $81.30 |
| 4 days before | 0% |
| 4 days after | 0% |
| On release day | 0% |
| Change in period | 0% |
| Release date | Feb 12, 2026 |
| Price on release | $78.95 |
| EPS estimate | $2.32 |
| EPS actual | $2.17 |
| EPS surprise | -6.47% |
| Date | Price |
|---|---|
| Feb 06, 2026 | $81.30 |
| Feb 09, 2026 | $81.30 |
| Feb 10, 2026 | $81.30 |
| Feb 11, 2026 | $81.30 |
| Feb 12, 2026 | $78.95 |
| Feb 13, 2026 | $78.95 |
| Feb 17, 2026 | $78.95 |
| Feb 18, 2026 | $78.95 |
| Feb 19, 2026 | $78.95 |
| 4 days before | -2.89% |
| 4 days after | 0% |
| On release day | 0% |
| Change in period | -2.89% |
Orion New B Shs Earnings Call Transcript Summary of Q4 2025
Orion reported an all-time high 2025 driven by strong performance across all divisions and a EUR 180 million sales milestone from Bayer related to Nubeqa. Q4 base-business sales grew 18.5% (60% including the milestone); Q4 operating profit was EUR 328 million and operating profit margin reached 47% for Q4 and 33.4% for the full year. Innovative Medicines became Orion's largest division, supported by rising Nubeqa royalties and product sales. R&D activity increased (including initiation of ODM-212 Phase II and planned biologics programs), driving higher R&D spend; sales & marketing costs are also expected to rise as the company invests in branded product growth and geographic expansion. Capital investments focus on Nubeqa API production and Easyhaler capacity. Management reiterated 2026 guidance: net sales EUR 1.9–2.1 billion and operating profit EUR 550–750 million. The Board proposes a dividend of EUR 1.80 per share. Key risk/variance drivers called out were Nubeqa dynamics (including post-LOE royalty step-downs), R&D sequencing and costs, and FX exposure (USD).
